AU1036701A - Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia - Google Patents

Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia

Info

Publication number
AU1036701A
AU1036701A AU10367/01A AU1036701A AU1036701A AU 1036701 A AU1036701 A AU 1036701A AU 10367/01 A AU10367/01 A AU 10367/01A AU 1036701 A AU1036701 A AU 1036701A AU 1036701 A AU1036701 A AU 1036701A
Authority
AU
Australia
Prior art keywords
salicilyc
acetyl
acid
treatment
benign prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU10367/01A
Inventor
Arturo San Feliciano
Maria Jose Montero Gomez
Maria Angeles Sevilla Toral
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INSTITUTO HELMAPROST SL
Original Assignee
INST HELMAPROST SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INST HELMAPROST SL filed Critical INST HELMAPROST SL
Publication of AU1036701A publication Critical patent/AU1036701A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU10367/01A 1999-10-19 2000-10-19 Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia Abandoned AU1036701A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9924766 1999-10-19
GBGB9924766.0A GB9924766D0 (en) 1999-10-19 1999-10-19 New use of acetyl salicilic acid
PCT/GB2000/004029 WO2001028566A1 (en) 1999-10-19 2000-10-19 Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia

Publications (1)

Publication Number Publication Date
AU1036701A true AU1036701A (en) 2001-04-30

Family

ID=10863019

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10367/01A Abandoned AU1036701A (en) 1999-10-19 2000-10-19 Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia

Country Status (3)

Country Link
AU (1) AU1036701A (en)
GB (1) GB9924766D0 (en)
WO (1) WO2001028566A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2385240B1 (en) * 2010-07-26 2013-09-23 Gp-Pharm, S.A. CAPSULES OF ACTIVE PHARMACEUTICAL PRINCIPLES AND POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF PROSTATE DISEASES.
US10105330B2 (en) 2012-01-04 2018-10-23 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437838A1 (en) * 1978-07-25 1980-04-30 Roecar Holdings Nv Prostaglandin inhibitors for benign adenoma of the prostate - includes salicylic, anthranilic and phenylacetic acid derivs., indole(s), indene(s), pyrrole(s) and pyrazolidine(s)
EP0372676A1 (en) * 1988-12-08 1990-06-13 Spyros Carantinos Therapeutic preparation and method
GB2306109B (en) * 1997-02-07 1997-09-24 John Wright A zinc containing composition as a common cold prophylactic

Also Published As

Publication number Publication date
WO2001028566B1 (en) 2001-10-11
WO2001028566A1 (en) 2001-04-26
GB9924766D0 (en) 1999-12-22

Similar Documents

Publication Publication Date Title
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
HUP0202477A3 (en) Use of phthalazine derivatives
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU7994200A (en) Compositions and methods for therapy and diagnosis of prostate cancer
DE60023982D1 (en) System for the treatment of benign prostatic hyperplasia
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU2212299A (en) Compositions and methods for the treatment of tumor
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
EP1176964B8 (en) Uses of et743 for treating cancer
AUPQ923100A0 (en) Treatment of prostate cancer
AU2235395A (en) Biological markers of benign prostate hyperplasia
AU2575201A (en) Use of hsp27 as an anti-inflammatory agent
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU6062900A (en) Substituted indole compounds and their use for the treatment of cancer
AU1916601A (en) Oncolytic combinations for the treatment of cancer
AU1878201A (en) Composition for the treatment of damaged tissue
AU1916501A (en) Oncolytic combinations for the treatment of cancer
AU1036701A (en) Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia
AU1595001A (en) Oncolytic combinations for the treatment of cancer
AU1917101A (en) Oncolytic combinations for the treatment of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 15, NO 32, PAGE(S) 6822-6826 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 10246/01, 10247/01, 10298/01, 10303/01, 10314/01, 10367/01, 10473/01, 10477/01, 11343/01, 11349/01, 11386/01, 11389/01, 11698/01, 11703/01, 11747/01, 11791/01, 12723/01, 12735/01, 13106/01, 13110/01, 13111/01, 13112/01, 13113/01, 13114/01, 13115/01 AND 16967/01

MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase